The Biosimilar Patent Dance Is Not a GameIts a Strategy Test. Heres How to Win It.
If youre a biologics innovator or a biosimilar applicant, you already know the patent dance isnt about choreographyits about leverage. The timing, the disclosures, the a…

Generic winners dont wait for exclusivitythey engineer it.
In the Paragraph IV world, the 180-day exclusivity clock is both prize and trap. It can create a first-mover advantageor become a costly delay that hands the market back to brand pharma. The …

The Patent Dance is no longer a dance—it’s a courtroom strategy.
For biologics and biosimilars, the BP(C)IA “dance” used to be viewed as a procedural hurdle: exchange notices, track deadlines, and hope the litigation doesn’t derail launch plans. But …

Big Pharma loves to talk about innovation. But the real competitive edge in drug development isnt just new moleculesits the data that predicts whats coming next.
In todays pharmaceutical supply chain, the winners arent only the companies with the deepe…

Patent cliffs don’t just threaten revenue—they can quietly reshape your supply chain.
When a blockbuster drug’s exclusivity ends, the market doesn’t simply “get cheaper.” It gets messier: new entrants, shifting manufacturing priorities, changing lead…

Generic drug margins are under siegeand the pressure isnt coming from one place. Its coming from eight directions at once.
Thats the core message behind DrugPatentWatchs breakdown of the 8 problems killing generic pharmas marginsand how the industry is…

Branded pharma’s revenue model is under siege—and it’s not just one problem. It’s a stack.
In a recent DrugPatentWatch post, the argument is blunt: the “branded” playbook—win big with a blockbuster, ride exclusivity, then defend share—has been hit from…

Generic drug entry isn’t just about science—it’s about timing.
If you’ve ever wondered how some generic manufacturers seem to “arrive” right when the market opens—often with surprising speed and precision—the answer is hiding in plain sight: the FDA …

Biopharma is hiring like its building a product roadmapexcept the product is often an IP portfolio.
Thats the real takeaway from a smart new piece on DrugPatentWatch: if you want to hire the right people for IP strategy, you cant treat patents like sta…

The generic cliff doesnt just happen. Pharma engineers itquietly, legally, and years in advance.
If youve ever wondered why some drugs seem to keep their pricing power long after the calendar says they shouldnt, the answer is rarely a single breakthrou…